VESIcare Approval History
FDA Approved: Yes (First approved November 19, 2004)
Brand name: VESIcare
Generic name: solifenacin
Dosage form: Tablets
Company: Yamanouchi / GlaxoSmithKline
Treatment for: Overactive Bladder
VESIcare (solifenacin) is a muscarinic receptor antagonist treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Development History and FDA Approval Process for VESIcare
|Nov 19, 2004||Vesicare Yamanouchi / GlaxoSmithKline - Treatment for Overactive Bladder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.